Skin Burns Drug Pipeline Analysis Report 2025
Description
Burns, a severe form of skin and tissue injury, impact over 11 million individuals annually, making them the fourth most common trauma globally. These injuries can result in life-altering complications, including infections, fluid imbalance, and significant scarring. Current treatments, such as wound dressings and surgical procedures, often fall short in addressing pain management, healing, and aesthetic recovery, highlighting a critical need for improved therapies. Advancements in biologics, regenerative medicine, and cutting-edge drug delivery technologies are driving innovation in this field, fostering a robust pipeline of treatments to address these unmet clinical needs and improve patient outcomes.
Report Coverage
The Skin Burns Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into skin burns therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for skin burns. The skin burns report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The skin burns pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with skin burns treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to skin burns.
Skin Burns Drug Pipeline Outlook
Skin burns are injuries to the skin caused by exposure to heat, chemicals, electricity, or radiation. These burns damage the skin layers, leading to pain, inflammation, and potential complications such as infection. Burns are categorized into first, second, and third-degree based on severity, with third-degree burns being the most severe. It requires immediate care to prevent infection and promote healing.
Skin burns treatment options include wound cleaning, dressings, and, in severe cases, skin grafts. Pain management, antibiotics, and advanced biologic therapies are increasingly utilized to enhance recovery, reduce scarring, and improve skin regeneration.
Skin Burns Epidemiology
Skin burns affect over 11 million people globally each year, with more than 90% of cases occurring in low- to middle-income countries, particularly in Africa, the Eastern Mediterranean, and South-East Asia. Severe burns, classified as ≥20% total body surface area (TBSA) in adults and ≥10% TBSA in children, result in a mortality rate of approximately 5%. Military burn casualties tend to have more severe injuries, often compounded by polytrauma and infections.
Skin Burns Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of skin burns drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total skin burns clinical trials.
Skin Burns Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the skin burns pipeline analysis include small molecules and monoclonal antibodies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for skin burns.
Skin Burns Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the skin burns report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in skin burns clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for skin burns. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of skin burns drug candidates.
Drug: Tranexamic Acid vs Thrombin JMI
The University of Kansas Medical Center is sponsoring a Phase 4 study that compares tranexamic acid and thrombin in managing split-thickness skin graft recipient sites for burns. The study aims to evaluate whether tranexamic acid is a cost-effective, non-inferior alternative to thrombin. With 62 participants, the study is expected to conclude in December 2026.
Biological: DenovoSkin(TM)
It is currently in a Phase III clinical trial and is an autologous dermo-epidermal skin substitute, for treating severe burns in adults and adolescents aged 12 and older. Sponsored by CUTISS AG, the study is intended to compare denovoSkin™ against split-thickness skin grafts to achieve wound closure and minimizing scarring. The trial, involving 70 participants, is expected to conclude by June 2028.
Drug: 4-Aminopyridine
The drug 4-Aminopyridine is being tested in a Phase 2 clinical study to accelerate healing in burn patients. Sponsored by the University of Arizona, the objective of this study is to evaluate the role of 4-AP in enhancing burn wound recovery. With around 200 enrolled patients, the study is expected to be completed by September 2028.
Reasons To Buy This Report
The Skin Burns Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for skin burns. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within skin burns pipeline insights.
Key Questions Answered in the Skin Burns – Pipeline Insight Report
Global Clinical Trials Market
Burn Pain Market
Report Coverage
The Skin Burns Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into skin burns therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for skin burns. The skin burns report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The skin burns pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with skin burns treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to skin burns.
Skin Burns Drug Pipeline Outlook
Skin burns are injuries to the skin caused by exposure to heat, chemicals, electricity, or radiation. These burns damage the skin layers, leading to pain, inflammation, and potential complications such as infection. Burns are categorized into first, second, and third-degree based on severity, with third-degree burns being the most severe. It requires immediate care to prevent infection and promote healing.
Skin burns treatment options include wound cleaning, dressings, and, in severe cases, skin grafts. Pain management, antibiotics, and advanced biologic therapies are increasingly utilized to enhance recovery, reduce scarring, and improve skin regeneration.
Skin Burns Epidemiology
Skin burns affect over 11 million people globally each year, with more than 90% of cases occurring in low- to middle-income countries, particularly in Africa, the Eastern Mediterranean, and South-East Asia. Severe burns, classified as ≥20% total body surface area (TBSA) in adults and ≥10% TBSA in children, result in a mortality rate of approximately 5%. Military burn casualties tend to have more severe injuries, often compounded by polytrauma and infections.
Skin Burns Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of skin burns drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Oral
- Intravenous
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total skin burns clinical trials.
Skin Burns Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the skin burns pipeline analysis include small molecules and monoclonal antibodies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for skin burns.
Skin Burns Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the skin burns report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in skin burns clinical trials:
- XenoTherapeutics, Inc.
- CUTISS AG
- Noveome Biotherapeutics
- Kuros Biosurgery AG
- Stratatech (a Mallinckrodt Company)
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for skin burns. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of skin burns drug candidates.
Drug: Tranexamic Acid vs Thrombin JMI
The University of Kansas Medical Center is sponsoring a Phase 4 study that compares tranexamic acid and thrombin in managing split-thickness skin graft recipient sites for burns. The study aims to evaluate whether tranexamic acid is a cost-effective, non-inferior alternative to thrombin. With 62 participants, the study is expected to conclude in December 2026.
Biological: DenovoSkin(TM)
It is currently in a Phase III clinical trial and is an autologous dermo-epidermal skin substitute, for treating severe burns in adults and adolescents aged 12 and older. Sponsored by CUTISS AG, the study is intended to compare denovoSkin™ against split-thickness skin grafts to achieve wound closure and minimizing scarring. The trial, involving 70 participants, is expected to conclude by June 2028.
Drug: 4-Aminopyridine
The drug 4-Aminopyridine is being tested in a Phase 2 clinical study to accelerate healing in burn patients. Sponsored by the University of Arizona, the objective of this study is to evaluate the role of 4-AP in enhancing burn wound recovery. With around 200 enrolled patients, the study is expected to be completed by September 2028.
Reasons To Buy This Report
The Skin Burns Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for skin burns. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within skin burns pipeline insights.
Key Questions Answered in the Skin Burns – Pipeline Insight Report
- Which companies/institutions are leading the skin burns drug development?
- What is the efficacy and safety profile of skin burns pipeline drugs?
- Which company is leading the skin burns pipeline development activities?
- What is the current skin burns commercial assessment?
- What are the opportunities and challenges present in the skin burns drug pipeline landscape?
- What is the efficacy and safety profile of skin burns pipeline drugs?
- Which company is conducting major trials for skin burns drugs?
- Which companies/institutions are involved in skin burns collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in skin burns?
Global Clinical Trials Market
Burn Pain Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Skin Burns
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Skin Burns
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Skin Burns: Epidemiology Snapshot
- 5.1 Skin Burns Incidence by Key Markets
- 5.2 Skin Burns – Patients Seeking Treatment in Key Markets
- 6 Skin Burns: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Skin Burns: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Skin Burns, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Skin Burns Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Skin Burns Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Tranexamic acid, Thrombin JMI
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Biological: denovoSkin(TM)
- 10.2.3 Other Drugs
- 11 Skin Burns Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: 4-Aminopyridine
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Bimatoprost
- 11.2.3 Other Drugs
- 12 Skin Burns Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Skin Burns Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Skin Burns, Key Drug Pipeline Companies
- 14.1 Xeno Therapeutics, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 CUTISS AG
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Noveome Biotherapeutics
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Kuros Biosurgery AG
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Stratatech (a Mallinckrodt Company)
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
